8.47
0.11 (1.32%)
| Previous Close | 8.36 |
| Open | 8.37 |
| Volume | 2,651,351 |
| Avg. Volume (3M) | 2,694,545 |
| Market Cap | 1,854,594,176 |
| Price / Sales | 33.26 |
| Price / Book | 3.24 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Operating Margin (TTM) | -597.47% |
| Diluted EPS (TTM) | -1.11 |
| Quarterly Revenue Growth (YOY) | -27.60% |
| Total Debt/Equity (MRQ) | 28.66% |
| Current Ratio (MRQ) | 10.22 |
| Operating Cash Flow (TTM) | -145.46 M |
| Levered Free Cash Flow (TTM) | -87.96 M |
| Return on Assets (TTM) | -27.21% |
| Return on Equity (TTM) | -57.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Ocular Therapeutix, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | 0.00 |
|
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.82% |
| % Held by Institutions | 87.01% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |